PDCD1 and neoplasm: These agents, such as pembrolizumab, function by blocking inhibitory immune checkpoints, like programmed cell death protein 1 (PD-1) or its ligand (PD-L1), thereby unleashing the host’s anti-tumor immune response [1,3].